Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05382286
Title Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Gilead Sciences

triple-receptor negative breast cancer


Pembrolizumab + Sacituzumab govitecan-hziy

Carboplatin + Gemcitabine + Pembrolizumab

Paclitaxel + Pembrolizumab

Nab-paclitaxel + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.